Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr Tan on the Management of ADC-Related Toxicities in Breast Cancer

August 28th 2025

Antoinette Tan, MD, MHS, discusses the safety profiles of ADCs and ADC selection considerations for breast cancer.

FDA to Review Gedatolisib NDA in HR+/HER2–, PIK3CA Wild-Type Advanced Breast Cancer

August 28th 2025

The FDA has agreed to review an NDA submission for gedatolisib in hormone receptor–positive/HER2-negative, PIK3CA wild-type advanced breast cancer.

Some Breast Tumors Tunnel Into Fat to Fuel Up. Can We Stop Them?

August 28th 2025

UCSF researchers have discovered that the cells of triple-negative breast cancer tumors build molecular tunnels into nearby fat cells.

De-Escalated Surgical Strategies for Locoregional Breast Cancer Expand to Broader Populations

August 28th 2025

Tari A. King, MD, FACS, FSSO, FASCO, discusses locoregional breast cancer management strategies and avoiding lymph node dissection in select patients.

Weight Loss Trial Reports Success for Breast Cancer Patients at One Year Mark

August 27th 2025

Findings from the Breast Cancer Weight Loss (BWEL) clinical trial set the stage for ongoing research to determine if weight loss following breast cancer treatment can reduce the risk of cancer recurrence and extend survival.

Adjuvant Abemaciclib Plus Endocrine Therapy Improves OS in High-Risk HR+/HER2– Breast Cancer

August 27th 2025

The addition of abemaciclib to endocrine therapy after surgery improved OS in patients with HR-positive, HER2-negative breast cancer with positive nodes.

Dermatologists Guide Oncology Teams to Recognize and Treat Breast Cancer Treatment–Associated Skin AEs

August 26th 2025

Jonathan Leventhal, MD, discusses the prevalence of breast cancer treatment–associated dermatologic AEs and the need for multidisciplinary management.

Dr Sarma on the Current Role of Sentinel Node Biopsies in Breast Cancer

August 25th 2025

Deba Sarma, MD, highlights the role of sentinel node biopsies ahead of surgery for the treatment of patients with breast cancer.

Dato-DXd Approved in China for Previously Treated HR+, HER2– Negative Metastatic Breast Cancer

August 25th 2025

Datopotamab deruxtecan is approved in China for hormone receptor–positive, HER2-negative metastatic breast cancer after prior endocrine therapy and chemotherapy.

Dr Cardoso on Outcomes With Elinzanetant for Hot Flashes in HR+ Breast Cancer

August 22nd 2025

Fatima Cardoso, MD, MSc, FESMO, discusses quality-of-life outcomes with elinzanetant for the management of hot flashes in hormone receptor–positive breast cancer.

Genomic Tests for HR+/HER2– Early Breast Cancer Show Utility Beyond Predicting Prognosis

August 22nd 2025

Joyce O'Shaughnessy, MD, discusses the utility of genomic testing in HR+, HER2– early breast cancer.

Oncology Conferences to Watch in the Second Half of 2025

August 20th 2025

Upcoming oncology meetings in the second half of 2025 will present new data across tumor types and offering updates that may influence standards of care.

Five Under 5: Top Oncology Videos for the Week of 8/10

August 17th 2025

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.

The OncFive: Top Oncology Articles for the Week of 8/10

August 16th 2025

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.

Neoadjuvant Olaparib Plus Carboplatin Reduces Residual Cancer Burden in BRCA1/2-Mutated, HRD+ TNBC

August 15th 2025

Neoadjuvant olaparib plus carboplatin led to a high RCB 0/1 rate in BRCA1/2-mutated, HRD+ TNBC.

Dr Ansley on the Role of Elacestrant in ER+/HER2– Advanced Breast Cancer

August 12th 2025

Katherine C. Ansley, MD, highlights the role of elacestrant in treating ER-positive, HER2-negative, ESR1-mutant, advanced breast cancer with metastases.

Real-World Outcomes Support Use of First-Line Palbociclib Plus ET in HR+/HER2– Advanced Breast Cancer

August 12th 2025

Real-world data supported the clinical effectiveness of first-line palbociclib plus endocrine therapy in HR-positive, HER2-negative breast cancer.

FDA Accepts NDA for Vepdegestrant in ESR1-Mutated, ER+/HER2– Breast Cancer

August 10th 2025

The FDA accepted an NDA for vepdegestrant in ER-positive, HER2-negative advanced breast cancer harboring ESR1 mutations after prior endocrine therapy.

OncLive’s July EMA Regulatory Recap: Key EU Approvals in Oncology

August 6th 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.

Coordinated Care in Breast Oncology: Encouraging Participation in Clinical Trials

August 4th 2025

Experts reflect on the power of clinical trial participation, multidisciplinary collaboration, and innovation to personalize care.